Pyrimidine-2,4-diamine derivatives for treatment of cancer

1. A compound of formula I,

or a pharmaceutically acceptable salt thereof, wherein:

R 1 represents aryl represented by

E 3 and E 4 each independently represent hydrogen, and

E 1 represents —F and E 2 represent —F, —Cl, —CH 3 or —CF 3 , or

E 1 represents —Cl and E 2 represents —F, —Cl, —CH 3 or —CF 3 , or

E 1 represents —CH 3 and E 2 represents —F, —Cl, —CH 3 , —CF 3 or —CN;

R 2 represents hydrogen;

R 3 represents —C 2-6 alkyl substituted by one Z 1 ;

Z 1 represents —N(R f2 )R g2 , —OR q2 , or aryl represented by

R f2 represents hydrogen;

R g2 and R q2 represent aryl optionally substituted by one or more substituents selected from W 6 , or heteroaryl optionally substituted by one or more substituents selected from W 6 ;

each W 6 independently represents halogen, —R a3 , —CN, —C(O)R b3 , —C(O)N(R c3 )R d3 ,—C(O)OR e3 , —N(R f3 )R g3 , —N(R h3 )C(O)R i3 , —N(R j3 )C(O)OR k3 , —N(R l3 )C(O)N(R m3 )R n3 , —N(R o3 )S(O) 2 R p3 , —OR q3 , —OC(O)R r3 , —OS(O) 2 R s3 , —S(O) m R t3 , —S(O) 2 N(R u3 )R v3 , heterocycloalkyl optionally substituted by one or more substituents selected from G 1 , aryl optionally substituted by one or more substituents selected from G 2 , heteroaryl optionally substituted by one or more substituents selected from G 2 , or ═O;

W 7 and W 11 each represent hydrogen;

W 8 and W 10 independently represent hydrogen, halogen, —R a3 , —CN, —C(O)R b3 , —C(O)N(R c3 )R d3 , —C(O)OR e3 , —N(R f3 )R g3 , —N(R h3 )C(O)R i3 , —N(R j3 )C(O)OR k3 , —N(R l3 )C(O)N(R m3 )R n3 , —N(R o3 )S(O) 2 R p3 , —OR q3 , —OC(O)R r3 , —OS(O) 2 R s3 , —S(O) m R t3 , —S(O) 2 N(R u3 )R v3 , heterocycloalkyl optionally substituted by one or more substituents selected from G 1 , aryl optionally substituted by one or more substituents selected from G 2 , or heteroaryl optionally substituted by one or more substituents selected from G 2 ;

W 9 represents halogen, —R a3 , —CN, —C(O)R b3 , —C(O)N(R c3 )R d3 , —C(O)OR e3 , —N(R f3 )R g3 , —N(R h3 )C(O)R i3 , —N(R j3 )C(O)OR k3 , —N(R l3 )C(O)N(R m3 )R n3 , —N(R o3 )S(O) 2 R p3 , —OR q3x , —OC(O)R r3 , —OS(O) 2 R s3 , —S(O) m R t3 , —S(O) 2 N(R u3 )R v3 , heterocycloalkyl optionally substituted by one or more substituents selected from G 1 , aryl optionally substituted by one or more substituents selected from G 2 , or heteroaryl optionally substituted by one or more substituents selected from G 2 ;

each R a3 , R b3 , R c3 , R d3 , R e3 , R f3 , R h3 , R i3 , R j3 , R l3 , R m3 , R n3 , R o3 , R q3 , R r3 , R t3 , R u3 and R v3 independently represents hydrogen or —C 1-6 alkyl optionally substituted by one or more G 3 ; or

any two R c3 and R d3 , R f3 and R g3 , R m3 and R n3 and/or R u3 and R v3 are linked together to form, along with the nitrogen atom to which they are attached, a 4- to 6-membered ring, which ring optionally contains one heteroatom and which ring optionally is substituted by one or more G 2 ; each R g3 , R k3 , R p3 , and R s3 independently represent C 1-6 alkyl optionally substituted by one or more G 3 ;

R q3x represents C 2-6 alkyl optionally substituted by one or more G 3 ;

each G 1 and G 2 independently represents halogen, —R a4 , —CN, —C(O)R b4 , —C(O)N(R c4 )R d4 , —C(O)OR e4 , —N(R f4 )R g4 , —N(R h4 )C(O)R i4 , —N(R j4 )C(O)OR k4 , —N(R l4 )C(O)N(R m4 )R n4 , —N(R o4 )S(O) 2 R p4 , —OR q4 , —OC(O)R r4 , —OS(O) 2 R s4 , —S(O) m R t4 , —S(O) 2 N(R u4 )R v4 , or ═O;

G 3 represents halogen, —CN, —C(O)R b4 , —C(O)N(R c4 )R d4 , —C(O)OR e4 , —N(R f4 )R g4 , —N(R h4 )C(O)R i4 , —N(R j4 )C(O)OR k4 , —N(R l4 )C(O)N(R m4 )R n4 , —N(R o4 )S(O) 2 R p4 , —OR q4 , —OC(O)R r4 , —OS(O) 2 R s4 , —S(O) m R t4 , —S(O) 2 N(R u4 )R v4 , or ═O;

each R a4 , R b4 , R c4 , R d4 , R e4 , R f4 , R h4 , R i4 , R j4 , R l4 , R m4 , R n4 , R o4 , R q4 , R r4 , R t4 , R u4 and R v4 independently represents hydrogen or —C 1-6 alkyl optionally substituted by one or more —F; or

any two R c4 and R d4 , R f4 and R g4 , R m4 and R n4 and/or R u4 and R v4 are linked together to form, along with the nitrogen atom to which they are attached, a 3- to 6-membered ring, which ring is optionally substituted by one or more —F, —CH 3 , —CH 2 CH 3 , —CHF 2 , —CF 3 , —CH 2 CF 3 , or ═O;

each R g4 , R k4 , R p4 and R s4 independently represent C 1-6 alkyl optionally substituted by one or more —F; and

each m independently represents 0, 1 or 2.

2. The compound as claimed in claim 1 , wherein

E 1 represents —Cl and E 2 represents —F, —Cl, —CH 3 or —CF 3 , or

E 1 represents —CH 3 and E 2 represents —F, —Cl, —CH 3 , —CF 3 or —CN.

3. The compound as claimed in claim 1 , wherein each W 6 independently represents —F, —Cl, —Br, —CH 3 , cyclopropyl, —CF 3 , —CN, —N(CH 3 ) 2 , —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 N(CH 3 ) 2 .

4. The compound as claimed in claim 1 , wherein

W 8 and W 10 each represents hydrogen; and

W 9 represents halogen, —R as , —CN, —C(O)R b3 , —C(O)N(R c3 )R d3 , —C(O)OR e3 , —N(R f3 )R g3 , —N(R h3 )C(O)R i3 , —N(R j3 )C(O)OR k3 , —N(R l3 )C(O)N(R m3 )R n3 , —N(R o3 )S(O) 2 R p3 , —OR q3x , —S(O) m R t3 , —S(O) 2 N(R u3 )R v3 , heterocycloalkyl optionally substituted by one or more substituents selected from G 1 , aryl optionally substituted by one or more substituents selected from G 2 , or heteroaryl optionally substituted by one or more substituents selected from G 2 .

5. The compound as claimed in claim 1 , wherein

W 8 and W 10 each represents hydrogen; and

W 9 represents —F, —Cl, —CH 3 , cyclopropyl, —CF 3 , —CN, —NH 2 , —N(CH 3 ) 2 , —N(H)C(O)CH 3 , —N(H)C(O)OC(CH 3 ) 3 , —SO 2 CH 3 , —SO 2 NH 2 , —S(O) 2 N(CH 3 ) 2 , —S(O) 2 -4-morpholinyl, 4-methylpiperazin-1-yl, 4-methylpiperidin-1-ylmethyl or 1,2,3-thiadiazol-4-yl.

6. The compound as claimed in claim 1 , wherein Z 1 represents —N(R f2 )R g2 .

7. The compound as claimed in claim 6 , wherein each W 6 independently represents —F, —Cl, —Br, —CH 3 , cyclopropyl, —CF 3 , —CN, —N(CH 3 ) 2 , —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 N(CH 3 ) 2 .

8. The compound as claimed in claim 1 , wherein Z 1 represents —OR q2 .

9. The compound as claimed in claim 8 , wherein each W 6 independently represents —F, —Cl, —Br, —CH 3 , cyclopropyl, —CF 3 , —CN, —N(CH 3 ) 2 , —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 N(CH 3 ) 2 .

10. The compound as claimed in claim 1 , wherein Z 1 represents aryl represented by

11. The compound as claimed in claim 10 , wherein

W 8 and W 10 each represents hydrogen; and

W 9 represents halogen, —R a3 , —CN, —C(O)R b3 , —C(O)N(R c3 )R d3 , —C(O)OR e3 , —N(R f3 )R g3 , —N(R h3 )C(O)R i3 , —N(R j3 )C(O)OR k3 , —N(R l3 )C(O)N(R m3 )R n3 , —N(R o3 )S(O) 2 R p3 , —OR q3x , —S(O) m R t3 , —S(O) 2 N(R u3 )R v3 , heterocycloalkyl optionally substituted by one or more substituents selected from G 1 , aryl optionally substituted by one or more substituents selected from G 2 , or heteroaryl optionally substituted by one or more substituents selected from G 2 .

12. The compound as claimed in claim 10 , wherein

W 8 and W 10 each represents hydrogen; and

W 9 represents —F, —Cl, —CH 3 , cyclopropyl, —CF 3 , —CN, —NH 2 , —N(CH 3 ) 2 , —N(H)C(O)CH 3 , —N(H)C(O)OC(CH 3 ) 3 , —SO 2 CH 3 , —SO 2 NH 2 , —S(O) 2 N(CH 3 ) 2 , —S(O) 2 -4-morpholinyl, 4-methylpiperazin-1-yl, 4-methylpiperidin-1-ylmethyl or 1,2,3-thiadiazol-4-yl.

13. The compound as claimed in claim 1 , wherein

E 1 represents —Cl, and E 2 represents —F, —Cl, —CH 3 or —CF 3 , or

E 1 represents —CH 3 , and E 2 represents —F, —Cl, —CH 3 , —CF 3 or —CN;

each W 6 independently represents —F, —Cl, —Br, —CH 3 , cyclopropyl, —CF 3 , —CN, —N(CH 3 ) 2 , —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 N(CH 3 ) 2 ;

W 8 and W 10 each represents hydrogen; and

W 9 represents —F, —Cl, —CH 3 , cyclopropyl, —CF 3 , —CN, —NH 2 , —N(CH 3 ) 2 , —N(H)C(O)CH 3 , —N(H)C(O)OC(CH 3 ) 3 , —SO 2 CH 3 , —SO 2 NH 2 , —S(O) 2 N(CH 3 ) 2 , —S(O) 2 -4-morpholinyl, 4-methylpiperazin-1-yl, 4-methylpiperidin-1-ylmethyl or 1,2,3-thiadiazol-4-yl.

14. A compound as claimed in claim 1 , selected from

6-(2,3-dimethylphenyl)-4-N-(2-phenylethyl)pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-[2-(4-methylphenyl)ethyl]pyrimidine-2,4-diamine;

4-N-[2-(4-chlorophenyl)ethyl]-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-(2-phenylpropyl)pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-(3-phenylpropyl)pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-(2-phenoxyethyl)pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-[2-(phenylamino)ethyl]pyrimidine-2,4-diamine;

6-(3-chloro-2-methyl-phenyl)-N4-[2-(3-methylsulfonylanilino)ethyl]pyrimidine-2,4-diamine

6-(2-chloro-3-methylphenyl)-4-N-[2-(4-chlorophenyl)ethyl]pyrimidine-2,4-diamine;

4-N-[2-(2-chlorophenoxy)ethyl]-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-[2-(pyridin-3-yloxy)propyl]pyrimidine-2,4-diamine;

4-N-[2-(4-chlorophenyl)ethyl]-6-(2,3-dichlorophenyl)pyrimidine-2,4-diamine;

4-N-[2-(4-chlorophenyl)cyclopropyl]-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-N-{[1-(4-chlorophenyl)cyclopropyl]methyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-(2-{[2-amino-6-(2,3-dichlorophenyl)pyrimidin-4-yl]amino}ethyl)benzene-1-sulfonamide;

4-(2-{[2-amino-6-(3-chloro-2-methylphenyl)pyrimidin-4-yl]amino}ethyl)benzene-1-sulfonamide;

6-[2-[[2-amino-6-(2,3-dichlorophenyl)pyrimidin-4-yl]amino]ethylamino]-2,2-dimethyl-4H-1,4-benzoxazin-3-one;

4-(2-{[2-Amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)benzene-1-sulfonamide;

6-(2,3-Dimethylphenyl)-4-N-[2-(4-methanesulfonylphenyl)ethyl]pyrimidine-2,4-diamine;

4-(2-{[2-Amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)benzonitrile;

4-(2-{[2-Amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethoxy)benzonitrile;

4-N-[2-(3-Chlorophenyl)ethyl]-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-N-[2-(4-Chlorophenyl)propyl]-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

6-(2,3-Dimethylphenyl)-4-N-[2-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine;

N-[3-(3-{[2-Amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}propoxy)phenyl]acetamide;

4-N-{2-[(1,3-Benzoxazol-2-yl)amino]ethyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

6-(2,3-Dimethylphenyl)-4-N-(4-phenylbutan-2-yl)pyrimidine-2,4-diamine;

6-[(2-{[2-Amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)amino]pyridine-3-carbonitrile;

4-N-{2-[(3-Bromo-1,2,4-thiadiazol-5-yl)amino]ethyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

6-(2,3-Dimethylphenyl)-4-N-[2-(4-methanesulfonylphenyl)ethyl]pyrimidine-2,4-diamine;

4-(2-{[2-amino-6-(3-chloro-2-methylphenyl)pyrimidin-4-yl]amino}ethyl)-N,N-dimethylbenzene-1-sulfonamide;

4-(2-{[2-amino-6-(2,3-dichlorophenyl)pyrimidin-4-yl]amino}ethyl)-N,N-dimethylbenzene-1-sulfonamide;

4-(2-{[2-amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)-N,N-dimethylbenzene-1-sulfonamide;

4-N-{1-[(4-Chlorophenyl)methyl]cyclopropyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-(2-{[2-amino-6-(3-cyano-2-methylphenyl)pyrimidin-4-yl]amino}ethyl)benzene-1-sulfonamide;

4-N-{2-[(6-chloropyridazin-3-yl)amino]ethyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

2-[(2-{[2-amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)amino]pyridine-4-carbonitrile;

6-[(2-{[2-amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)amino]pyridine-3-sulfonamide;

6-(2,3-dichlorophenyl)-4-N-[2-(4-methanesulfonylphenyl)ethyl]pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-{2-[(3-methoxyphenyl)amino]ethyl}pyrimidine-2,4-diamine;

6-(2,3-dimethylphenyl)-4-N-{2-[(3-fluoro-4-methylphenyl)amino]ethyl}pyrimidine-2,4-diamine;

4-N-{2-[(3,4-dichlorophenyl)amino]ethyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-N-{2-[(5-chloropyridin-2-yl)amino]ethyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-N-{2-[(5-bromopyridin-2-yl)amino]ethyl}-6-(2,3-dimethylphenyl)pyrimidine-2,4-diamine;

4-[(2-{[2-amino-6-(2,3-dimethylphenyl)pyrimidin-4-yl]amino}ethyl)amino]benzene-1-sulfonamide; and

6-(2,3-dimethylphenyl)-4-N-{2-[(pyridin-3-yl)amino]ethyl}pyrimidine-2,4-diamine;

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical formulation comprising a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

16. A method of treatment of a disease selected from the group consisting of soft tissue cancers selected from the group consisting of sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and teratoma;

lung cancers/diseases selected from the group consisting of bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma;

gastrointestinal cancers/diseases selected from the group consisting of cancers of the esophagus, stomach, pancreas, small bowel, and large bowel;

genitourinary tract cancers/diseases selected from the group consisting of cancers of the kidney, bladder and urethra, prostate, and testis;

liver cancers/diseases selected from the group consisting of hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma;

bone cancers/diseases selected from the group consisting of osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors;

nervous system cancers/diseases selected from the group consisting of cancer of the skull, meninges, brain, and spinal cord;

gynecological cancers/diseases selected from the group consisting of uterus, cervix, ovaries, vulva, and vagina;

hematologic cancers;

skin cancers/diseases selected from the group consisting of malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids;

adrenal glands cancers/diseases, neuroblastoma, neurofibromatosis, head and neck cancers; and breast cancers

wherein the method comprises administering a therapeutically effective amount a compound as claimed in claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment; and

wherein the treatment does not comprise prevention or prophylaxis.

17. The method as claimed in claim 16 , wherein the disease is selected from the group consisting of breast cancers, prostate cancers, lung cancers, oesophageal cancers, colon cancers, brain cancers, skin cancers, ovarian cancers, testicular cancers, neurofibromatosis and leukemias.

18. A combination product comprising:

(A) compound as claimed in claim 1 , or a pharmaceutically acceptable salt thereof; and

(B) one or more other therapeutic agent(s) that is/are useful in the treatment of a disease,

wherein each one of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and

wherein the treatment does not comprise prevention or prophylaxis;

wherein the disease is selected from the group consisting of soft tissue cancers selected from the group consisting of sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and teratoma;

lung cancers/diseases selected from the group consisting of bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma;

gastrointestinal cancers/diseases selected from the group consisting of cancers of the esophagus, stomach, pancreas, small bowel, and large bowel;

genitourinary tract cancers/diseases selected from the group consisting of cancers of the kidney, bladder and urethra, prostate, and testis;

liver cancers/diseases selected from the group consisting of hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma;

bone cancers/diseases selected from the group consisting of osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors;

nervous system cancers/diseases selected from the group consisting of cancer of the skull, meninges, brain, and spinal cord;

gynecological cancers/diseases selected from the group consisting of uterus, cervix, ovaries, vulva, and vagina;

hematologic cancers;

skin cancers/diseases selected from the group consisting of malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids;

adrenal glands cancers/diseases, neuroblastoma, neurofibromatosis, head and neck cancers; and breast cancers.

19. The combination product as claimed in claim 18 , wherein the disease is selected from the group consisting of breast cancers, prostate cancers, lung cancers, oesophageal cancers, colon cancers, brain cancers, skin cancers, ovarian cancers, testicular cancers, neurofibromatosis and leukemias.

20. The combination product as claimed in claim 18 , wherein component (B) is selected from the group consisting of anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors; kinase inhibitors; angiogenesis inhibitors; immunotherapeutic agents; pro-apoptotic agents; and cell cycle signaling inhibitors.